UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V.n(Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a nclinical-stage oncology company developing innovative, full-length nmultispecific antibodies (Biclonics® and Triclonics®), presented nclinical data on zenocutuzumab (Zeno) in combination with trastuzumab nand vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) nmetastatic breast cancer (MBC) who had progressed on anti-HER2 antibody ndrug conjugates (ADC), at the San Antonio Breast Cancer Symposium in SannAntonio, Texas.
The Vinorelbine market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional markets and also market competitors. The report estimates the performance of the key players by 2024 .
Taiwan Liposome Company (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, is pleased to announce that it has closed its 2019 cash capital offering of ordinary or common shares in Taiwan.
Ingenus Pharms`s Generic Vinorelbine Tartrate Receives Approval in US
JIANGSU YEW Pharmaceutical Co. Ltd. Fails EDQM Inspection
Five drugs suspended after factory inspection
Olaparib (Lynparza) is a treatment for advanced ovarian cancer in patients carrying inherited mutations in the BRCA gene. A study compares olaparib with standard drugs for the treatment of metastatic breast cancer in patients with inherited BRCA mutation.
Anetumab ravtansine is an antibody-drug conjugate that recognizes and binds to mesothelin, the protein that is over-produced in mesothelioma and other cancers. Binding to mesothelin allows the drug to enter a tumor cell, where it can destroy enzymes necessary for cell division and survival. The result is tumor cell death.
AstraZeneca announced positive results from its Phase III trial comparing Lynparza (olaparib) tablets to physician’s choice of a standard of care chemotherapy, in the treatment of patients with HER2-negative metastatic breast cancer, harbouring germline BRCA1 or BRCA2 mutations.
Zhejiang Hisun Pharmaceutical, Co., Ltd. (Yantou Campus) Fails EDQM Inspection